KOSDAQBiotech & Pharma335810

Precision Biosensor

₩1,331▲ 0.08%2026-11-18 close
Market Cap
₩29.2B
Turnover
₩7,293,929
Volume
5.5K
Shares out.
22M
PER
—
PBR
0.7×
EPS
-₩331
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating profit returns, net losses persist

Precision Biosensor returned to operating profit in the third quarter of 2026, but net losses attributable to shareholders and a four-year run of annual operating losses remain.

  1. 1

    Operating profit in the third quarter of 2026 was KRW 412 million, turning from a loss a year earlier, while revenue of KRW 7.02 billion rose 37.2% year on year.

  2. 2

    The company recorded losses for four consecutive years from 2022 to 2025, with an operating loss of KRW 5.38 billion and a net loss attributable to owners of the parent of KRW 10 billion in 2025.

  3. 3

    Net losses attributable to owners of the parent continued in the second and third quarters of 2026, and the four-quarter total from the fourth quarter of 2025 through the third quarter of 2026 was KRW 5.35 billion.

  4. 4

    The company completed a merger with a related company in February 2026, and Kwangdong Pharmaceutical held 50.23% as of the February 9, 2026 disclosure.

  5. 5

    A rapid influenza test from its US subsidiary received full FDA approval in January 2026, and its veterinary clinical chemistry analyzer launched in Japan in June 2026.

02

Business structure

Precision Biosensor is an in-vitro diagnostics company that supplies analyzers and reagent cartridges to hospitals and testing laboratories. Its business is divided into immunodiagnostics and clinical chemistry diagnostics.

Immunodiagnostic products are used across cardiovascular disease, infectious disease, hormones and cancer. Clinical chemistry products, launched in 2021, became the main business, accounting for more than 70% of total revenue from 2023 according to a report in early 2025.

The clinical chemistry line covers products for humans and animals, and the veterinary analyzers and cartridges are sold in overseas markets including Europe and Asia.

Its US subsidiary handles rapid test kits for respiratory infections such as COVID-19 and influenza, and its influenza rapid test received full FDA approval in January 2026.

Peers such as Celltrion and Samsung Biologics center on biopharmaceutical manufacturing, whereas this company sells diagnostic devices and consumables.

In North America, a planned entry based on a 2022 long-term veterinary clinical chemistry supply contract stalled after a partner was involved in an acquisition, and the company has sought new partners while shifting existing contract volumes to Europe, Asia and the Middle East. Its largest shareholder changed from iSens to Kwangdong Pharmaceutical in 2024.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.1B-₩1B−20.1%
2025Q4₩5.3B-₩1.4B−26.4%
2026Q1₩7B₩17,458,4000.2%
2026Q2₩6.2B-₩1.2B−19.5%
2026Q3₩7B₩400M5.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩20.5B-₩4.5B-₩6.8B−22.0%−20.4%76.8%
2023₩20.4B-₩4.8B-₩4.5B−23.6%−14.0%95.1%
2024₩19.1B-₩5.4B-₩7.3B−28.0%−28.4%102.5%
2025₩19.9B-₩5.4B-₩10B−27.0%−30.6%62.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue was KRW 20.5 billion in 2022, KRW 20.4 billion in 2023 (down 0.3% year on year), KRW 19.1 billion in 2024 (down 6.2%) and KRW 19.9 billion in 2025 (up 4.1%). Among 2022 to 2025, 2022 was the largest year and 2024 the smallest.

Operating losses over the same period were KRW 4.5 billion in 2022, KRW 4.81 billion in 2023, KRW 5.37 billion in 2024 and KRW 5.38 billion in 2025, with operating margins of -22.0%, -23.6%, -28.0% and -27.0%. The company recorded losses for four consecutive years from 2022 through 2025.

The net loss attributable to owners of the parent narrowed from KRW 6.81 billion in 2022 to KRW 4.49 billion in 2023, then widened to KRW 7.31 billion in 2024 and KRW 10 billion in 2025.

The 2025 operating loss was little changed from 2024, so the larger 2025 net loss is best read against the impairment of tangible and intangible assets that the company cited as the main driver. The debt-to-equity ratio fell from 102.5% in 2024 to 62.0% in 2025.

Total equity at the end of 2025 was KRW 32.8 billion, all of it attributable to owners of the parent, and total liabilities were KRW 20.3 billion. Operating cash flow was negative in every year, at -KRW 2.58 billion in 2022, -KRW 1.95 billion in 2023, -KRW 1.44 billion in 2024 and -KRW 1.51 billion in 2025.

By quarter, the third quarter of 2025 showed revenue of KRW 5.12 billion and an operating loss of KRW 1.03 billion, and the fourth quarter widened the operating loss to KRW 1.4 billion on revenue of KRW 5.29 billion.

Revenue in the first quarter of 2026 was KRW 7.03 billion, up 32.8% from the prior quarter, and operating profit of KRW 17.46 million turned the result positive. In the second quarter, revenue fell 11.6% to KRW 6.22 billion and the operating loss of KRW 1.21 billion returned.

The third quarter of 2026 recorded revenue of KRW 7.02 billion and operating profit of KRW 412 million.

Net profit attributable to owners of the parent was KRW 133 million in the first quarter of 2026, followed by a net loss of KRW 1.17 billion in the second quarter and KRW 519 million in the third quarter, which means two consecutive quarters of losses.

In an interview reported in late August 2026, the CEO said first-half 2026 revenue grew 39% year on year and the operating loss narrowed.

05

Industry analysis

The in-vitro diagnostics market has been normalizing since the COVID-19 demand surge ended. The company said the 2023 end of the pandemic weighed on domestic diagnostics makers and that it responded by expanding its clinical chemistry products.

The company also said demand for point-of-care testing solutions, which deliver results on site, is growing in global markets; this is the company's own view, and no independent market-size data was used here.

In North America, a report said that after a partner's acquisition, competitor products came to be sold on the basis of analyzers already installed at customer sites. In Europe, sales are also reportedly based on analyzers already in place.

In immunodiagnostics, FDA clearances are widening the company's room to enter the US market. Celltrion and Samsung Biologics center on drug manufacturing, whereas this company sells diagnostic devices and consumables to hospitals and testing laboratories.

Demand for diagnostic devices can move with hospital testing volumes, care settings and infectious disease activity, so it may respond differently from biopharmaceutical makers. The clinical chemistry line has expanded sales channels in Korea, Europe and Asia, while the North American channel is being restructured.

Product approvals and partner contracts therefore appear to explain revenue direction more than the broader sector cycle.

06

Outlook

The CEO has said the company aims to make 2026 the first year of a return to profit, and has described efforts to reorganize the business and improve the cost structure after the change in largest shareholder.

In the US, the influenza rapid test received full FDA approval in January 2026, and in May 2026 the company expanded a supply agreement with Sekisui for a combo rapid test. The veterinary clinical chemistry analyzer Atlyze V launched in Japan in June 2026.

In immunodiagnostics, three thyroid function point-of-care tests received European IVDR certification in June 2026, and in early August 2026 the company obtained domestic sales certification for its HbA1c immunodiagnostic product.

The North American veterinary clinical chemistry channel is being restructured after a partner change, so whether a new partner contract is signed is a key variable for revenue. A 2025 report said the company was moving existing contract volumes to Europe, Asia and the Middle East.

The second-quarter 2026 results were released on August 14, 2026, and third-quarter 2026 results were filed in a quarterly report in mid-November 2026.

Disclosures about repurchasing convertible bonds before maturity were filed on February 19, May 8, May 15 and August 18, 2026, so changes in the capital structure are ongoing.

The next checkpoints are whether operating profit stays positive across the full year in the 2026 annual report, and whether the US supply agreements and new product approvals show up in quarterly revenue.

07

Valuation

PER
—
PBR
0.7×
ROE
-17.6%
EPS
-₩331
BPS
₩1,948
Dividend per share
₩0

Because the net loss attributable to owners of the parent over the last four quarters is negative, earnings-based multiples cannot be calculated, and comparisons on earnings have limited meaning. The price-to-book ratio sits in a range below book value, meaning the share price is low relative to net assets.

Total equity of KRW 32.8 billion at the end of 2025 was entirely attributable to owners of the parent, with total liabilities of KRW 20.3 billion, and the debt-to-equity ratio fell from 102.5% in 2024 to 62.0% in 2025.

A discount to book value reflects the market's view of whether assets can produce returns, so whether assets contribute income after the 2025 impairment is the central interpretive question. Earnings-based comparisons become possible once profitable quarters accumulate, and that point will change how valuation is read.

The dividend yield is close to zero, so no shareholder return through dividends is in evidence. The high stake held by the largest shareholder also limits the float, which is a factor in reading the share price.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Operating profit turns positive in Q3 2026

Quarterly revenue stayed above KRW 6 billion through 2026, at KRW 7.03 billion in the first quarter, KRW 6.22 billion in the second and KRW 7.02 billion in the third. The CEO said first-half 2026 revenue grew 39% year on year. Whether operating profit stays positive beyond a single quarter is the point to watch for this strength.

Expanding product approvals in the US and abroad

The influenza rapid test from the US subsidiary received full FDA approval in January 2026, and in May 2026 the company expanded a supply agreement with Sekisui for a combo rapid test.

The veterinary analyzer Atlyze V launched in Japan in June 2026, and three thyroid function point-of-care tests received European IVDR certification. In early August 2026, the HbA1c immunodiagnostic product obtained domestic sales certification in Korea. As approvals accumulate, the product range and the number of markets where it can sell both widen.

Business reorganization under the new controlling shareholder

Kwangdong Pharmaceutical is the largest shareholder, and the company completed a merger with a related company in February 2026. The CEO said the business has been reorganized and the cost structure improved since the change in control. Operating profit turned positive in the third quarter of 2026 after the merger. The disclosed quarterly figures alone do not show how much of that improvement came from cost changes.

09

Bear factors

Recurring quarterly losses

The operating loss in the second quarter of 2026 was KRW 1.21 billion, so profitability lasted only one quarter. The net loss attributable to owners of the parent was KRW 1.17 billion in the second quarter and KRW 519 million in the third, meaning two consecutive quarters of losses.

The four-quarter total of KRW 5.35 billion equals about 16% of total equity at the end of 2025. The gap between operating profit and net profit is the main bearish point.

Weak execution of the North American contract

A long-term veterinary clinical chemistry supply contract signed in July 2022 was valued at about USD 91.33 million, but a 2025 report said supply recorded zero revenue in 2024 after a corrected disclosure. A partner's acquisition stalled the North American entry, and the existing contract was moved to other regions. The gap between contract value and actual execution weakens confidence in revenue forecasts.

Impairment charges and negative operating cash flow

The 2025 net loss of KRW 10 billion was attributed in disclosures to the recognition of impairment losses on tangible and intangible assets. Total liabilities at the end of 2025 were KRW 20.3 billion, lower than in 2024, but operating cash flow was still negative at -KRW 1.51 billion in 2025.

An impairment reflects a change in the accounting view of asset value, so whether those assets later generate income is the central bearish question.

10

Risk factors

Product and regional concentration

A 2025 report said clinical chemistry products accounted for more than 70% of total revenue from 2023. Revenue depends heavily on one product line and a few partner contracts, so a disruption in one channel can move quarterly results sharply. The 11.6% quarter-on-quarter revenue decline in the second quarter of 2026 is consistent with that volatility.

Largest shareholder stake and free float

Kwangdong Pharmaceutical's stake stood at 50.23% in the February 9, 2026 disclosure, after new shares were issued in the merger on February 4. With the largest holder close to a majority, the free float may be limited.

Business reorganization under the group and future strategic direction after the change in control are further variables.

Convertible bonds and capital structure

Disclosures about repurchasing convertible bonds before maturity were filed on February 19, May 8, May 15 and August 18, 2026, so the capital structure is still changing. Operating cash flow was negative in every year from 2022 to 2025.

Whether the business has shifted to funding itself from its own cash has not yet been shown in the reported figures.

11

What to watch next

  1. Mid-March 2027 (approx.)

    Filing of the 2026 annual report (the 2025 annual report was filed on March 17, 2026). Check whether the full-year operating margin and the net result attributable to owners align with the third-quarter 2026 profit, and whether year-end asset impairment review affects the figures.

  2. Late March 2027 (approx.)

    Release of fourth-quarter and full-year 2026 results (the fourth-quarter 2025 results were presented on March 26, 2026). Watch whether fourth-quarter operating profit stays positive and whether the full year ends in operating profit.

  3. Year-end closing on December 31, 2026

    The year-end closing includes the review of tangible and intangible asset impairment. Because impairment was the main driver of the 2025 net loss, how this review is reflected in the net income shown in the March 2027 annual report is a checkpoint.

  4. Around May 2027 (approx.)

    Release of first-quarter 2027 results (first-quarter 2026 results were released on May 15, 2026). Check whether operating profit stays positive after the first quarter and whether revenue from US supply agreements and newly approved products appears in quarterly figures.

12

Overall view

Precision Biosensor returned to operating profit in the third quarter of 2026, an early sign of recovery in its results. Quarterly revenue stayed above KRW 6 billion through 2026, and the CEO said first-half 2026 revenue grew 39% year on year.

Product approvals and overseas supply expansions were reported from January to August 2026. On the other side, net losses attributable to owners of the parent continued in the second and third quarters of 2026, and the four-quarter total was KRW 5.35 billion.

The company posted operating losses for four consecutive years from 2022 to 2025, and the 2025 net loss of KRW 10 billion was attributed mainly to impairment charges. The volatility of the North American veterinary contract, which stalled after a partner change, also explains swings in revenue.

The debt-to-equity ratio fell to 62.0% in 2025, but operating cash flow remained negative. On valuation, the price-to-book ratio sits in a range below net asset value, while earnings-based multiples cannot be calculated given the loss structure.

The next checkpoints are the operating margin in the 2026 annual report and whether first-quarter 2027 results continue the third-quarter 2026 profit trend.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. vegannews.co.kr
  2. comp.fnguide.com
  3. m.news.nate.com
  4. m.irgo.co.kr
  5. edaily.co.kr
  6. biotimes.co.kr
  7. mpharm.edaily.co.kr
  8. saramin.co.kr
  9. view.asiae.co.kr
  10. v.daum.net
  11. file.irgo.co.kr
  12. m.news.nate.com
  13. hankyung.com
  14. precision-bio.irpage.co.kr
  15. m.news.nate.com
  16. m.news.nate.com
  17. m.news.nate.com
  18. kr.investing.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis